Acadia Pharmaceuticals reaches preliminary settlement in derivative suit; $1.5M fees, four-year governance reforms
Acadia Pharmaceuticals reached a preliminary court-approved settlement of a stockholder derivative action requiring adoption of corporate governance reforms and a $1,500,000 fee for stockholders' counsel.Key Highlights:Original SEC Filing: ACADIA PHARMACEUTICALS INC [ ACAD ] - 8-K - Sep. 11, 2026Th…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.